Circulating Biomarkers of Endothelial Dysfunction Associated With Ventilatory Ratio and Mortality in ARDS Resulting From SARS-CoV-2 Infection Treated With Antiinflammatory Therapies

Overview

Journal CHEST Crit Care

Specialty Critical Care

Date 2024 Jul 22

PMID 39035722

Authors

Jehan W Alladina

Francesca L Giacona

Alexis M Haring

Kathryn A Hibbert

Benjamin D Medoff

Eric P Schmidt

Taylor Thompson

Bradley A Maron

George A Alba

Affiliations

Soon will be listed here.

Abstract

Background: The association of plasma biomarkers and clinical outcomes in ARDS resulting from SARS-CoV-2 infection predate the evidence-based use of immunomodulators.

Research Question: Which plasma biomarkers are associated with clinical outcomes in patients with ARDS resulting from SARS-CoV-2 infection treated routinely with immunomodulators?

Study Design And Methods: We collected plasma from patients with ARDS resulting from SARS-CoV-2 infection within 24 h of admission to the ICU between December 2020 and March 2021 (N = 69). We associated 16 total biomarkers of inflammation (eg, IL-6), coagulation (eg, D-dimer), epithelial injury (eg, surfactant protein D), and endothelial injury (eg, angiopoietin-2) with the primary outcome of in-hospital mortality and secondary outcome of ventilatory ratio (at baseline and day 3).

Results: Thirty patients (43.5%) died within 60 days. All patients received corticosteroids and 6% also received tocilizumab. Compared with survivors, nonsurvivors demonstrated a higher baseline modified Sequential Organ Failure Assessment score (median, 8.5 [interquartile range (IQR), 7-9] vs 7 [IQR, 5-8]); = .004), lower Pao to Fio ratio (median, 153 [IQR, 118-182] vs 184 [IQR, 142-247]; = .04), and higher ventilatory ratio (median, 2.0 [IQR, 1.9-2.3] vs 1.5 [IQR, 1.4-1.9]; < .001). No difference was found in inflammatory, coagulation, or epithelial biomarkers between groups. Nonsurvivors showed higher median neural precursor cell expressed, developmentally down-regulated 9 (NEDD9) levels (median, 8.4 ng/mL [IQR, 7.0-11.2 ng/mL] vs 6.9 ng/mL [IQR, 5.5-8.0 ng/mL]; = .0025), von Willebrand factor domain A2 levels (8.7 ng/mL [IQR, 7.9-9.7 ng/mL] vs 6.5 ng/mL [IQR, 5.7-8.7 ng/mL]; = .007), angiopoietin-2 levels (9.0 ng/mL [IQR, 7.9-14.1 ng/mL] vs 7.0 ng/mL [IQR, 5.6-10.6 ng/mL]; = .01), and syndecan-1 levels (15.9 ng/mL [IQR, 14.5-17.5 ng/mL] vs 12.6 ng/mL [IQR, 10.5-16.1 ng/mL]; = .01). Only NEDD9 level met the adjusted threshold for significance ( < .003). Plasma NEDD9 level was associated with 60-day mortality (adjusted OR, 9.7; 95% CI, 1.6-60.4; = .015). Syndecan-1 level correlated with both baseline (ρ = 0.4; = .001) and day 3 ventilatory ratio (ρ = 0.5; < .001).

Interpretation: Biomarkers of inflammation, coagulation, and epithelial injury were not associated with clinical outcomes in a small cohort of patients with ARDS uniformly treated with immunomodulators. However, endothelial biomarkers, including plasma NEDD9, were associated with 60-day mortality.

References

Gordon A, Mouncey P, Al-Beidh F, Rowan K, Nichol A, Arabi Y . Interleukin-6 Receptor Antagonists in Critically Ill Patients with Covid-19. N Engl J Med. 2021; 384(16):1491-1502. PMC: 7953461. DOI: 10.1056/NEJMoa2100433. View

Saleem N, Kulkarni A, Snow T, Ambler G, Singer M, Arulkumaran N . Effect of Corticosteroids on Mortality and Clinical Cure in Community-Acquired Pneumonia: A Systematic Review, Meta-analysis, and Meta-regression of Randomized Control Trials. Chest. 2022; 163(3):484-497. PMC: 10808071. DOI: 10.1016/j.chest.2022.08.2229. View

Alba G, Samokhin A, Wang R, Zhang Y, Wertheim B, Arons E . NEDD9 Is a Novel and Modifiable Mediator of Platelet-Endothelial Adhesion in the Pulmonary Circulation. Am J Respir Crit Care Med. 2021; 203(12):1533-1545. PMC: 8483217. DOI: 10.1164/rccm.202003-0719OC. View

. The GTEx Consortium atlas of genetic regulatory effects across human tissues. Science. 2020; 369(6509):1318-1330. PMC: 7737656. DOI: 10.1126/science.aaz1776. View

Monteiro A, Vangala S, Wick K, Delucchi K, Siegel E, Thompson B . The prognostic value of early measures of the ventilatory ratio in the ARDS ROSE trial. Crit Care. 2022; 26(1):297. PMC: 9521854. DOI: 10.1186/s13054-022-04179-7. View

Zhou I, Mascia M, Alba G, Magaletta M, Ginns L, Caravan P . Dynamic Contrast-enhanced MRI Demonstrates Pulmonary Microvascular Abnormalities Months After SARS-CoV-2 Infection. Am J Respir Crit Care Med. 2023; 207(12):1636-1639. PMC: 10273117. DOI: 10.1164/rccm.202210-1884LE. View

Calfee C, Delucchi K, Parsons P, Thompson B, Ware L, Matthay M . Subphenotypes in acute respiratory distress syndrome: latent class analysis of data from two randomised controlled trials. Lancet Respir Med. 2014; 2(8):611-20. PMC: 4154544. DOI: 10.1016/S2213-2600(14)70097-9. View

Sinha P, Calfee C, Beitler J, Soni N, Ho K, Matthay M . Physiologic Analysis and Clinical Performance of the Ventilatory Ratio in Acute Respiratory Distress Syndrome. Am J Respir Crit Care Med. 2018; 199(3):333-341. PMC: 6363976. DOI: 10.1164/rccm.201804-0692OC. View

Leisman D, Mehta A, Thompson B, Charland N, Gonye A, Gushterova I . Alveolar, Endothelial, and Organ Injury Marker Dynamics in Severe COVID-19. Am J Respir Crit Care Med. 2021; 205(5):507-519. PMC: 8906476. DOI: 10.1164/rccm.202106-1514OC. View

10.

Terpstra M, Aman J, van Nieuw Amerongen G, Groeneveld A . Plasma biomarkers for acute respiratory distress syndrome: a systematic review and meta-analysis*. Crit Care Med. 2013; 42(3):691-700. DOI: 10.1097/01.ccm.0000435669.60811.24. View

11.

. Baricitinib in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial and updated meta-analysis. Lancet. 2022; 400(10349):359-368. PMC: 9333998. DOI: 10.1016/S0140-6736(22)01109-6. View

12.

Horby P, Lim W, Emberson J, Mafham M, Bell J, Linsell L . Dexamethasone in Hospitalized Patients with Covid-19. N Engl J Med. 2020; 384(8):693-704. PMC: 7383595. DOI: 10.1056/NEJMoa2021436. View

13.

Parada-Gereda H, Avendano J, Melo J, Ruiz C, Castaneda M, Medina-Parra J . Association between ventilatory ratio and mortality in patients with acute respiratory distress syndrome and COVID 19: A multicenter, retrospective cohort study. BMC Pulm Med. 2023; 23(1):425. PMC: 10623871. DOI: 10.1186/s12890-023-02733-9. View

14.

Calfee C, Gallagher D, Abbott J, Thompson B, Matthay M . Plasma angiopoietin-2 in clinical acute lung injury: prognostic and pathogenetic significance. Crit Care Med. 2012; 40(6):1731-7. PMC: 3601049. DOI: 10.1097/CCM.0b013e3182451c87. View

15.

Brower R, Matthay M, Morris A, Schoenfeld D, Thompson B, Wheeler A . Ventilation with lower tidal volumes as compared with traditional tidal volumes for acute lung injury and the acute respiratory distress syndrome. N Engl J Med. 2000; 342(18):1301-8. DOI: 10.1056/NEJM200005043421801. View

16.

Bhatraju P, Morrell E, Zelnick L, Sathe N, Chai X, Sakr S . Comparison of host endothelial, epithelial and inflammatory response in ICU patients with and without COVID-19: a prospective observational cohort study. Crit Care. 2021; 25(1):148. PMC: 8054255. DOI: 10.1186/s13054-021-03547-z. View

17.

Ware L, Calfee C . Biomarkers of ARDS: what's new?. Intensive Care Med. 2015; 42(5):797-799. DOI: 10.1007/s00134-015-3973-0. View

18.

Calfee C, Janz D, Bernard G, May A, Kangelaris K, Matthay M . Distinct molecular phenotypes of direct vs indirect ARDS in single-center and multicenter studies. Chest. 2015; 147(6):1539-1548. PMC: 4451708. DOI: 10.1378/chest.14-2454. View

19.

Alba G, Samokhin A, Wang R, Wertheim B, Haley K, Padera R . Pulmonary endothelial NEDD9 and the prothrombotic pathophenotype of acute respiratory distress syndrome due to SARS-CoV-2 infection. Pulm Circ. 2022; 12(2):e12071. PMC: 9111030. DOI: 10.1002/pul2.12071. View

20.

Zheng M . Dead space ventilation-related indices: bedside tools to evaluate the ventilation and perfusion relationship in patients with acute respiratory distress syndrome. Crit Care. 2023; 27(1):46. PMC: 9894747. DOI: 10.1186/s13054-023-04338-4. View